Sino Biological launches XPressMAX Kit
Analysis based on 9 articles · First reported May 18, 2026 · Last updated May 19, 2026
The launch of the XPressMAX Cell-Free Protein Synthesis Kit by Sino Biological is expected to positively impact the biotechnology and pharmaceutical sectors by accelerating antibody drug discovery. This innovation could lead to increased efficiency and reduced costs in drug development, potentially boosting Sino Biological's stock performance and market share.
Sino Biological, a global leader in recombinant technology, announced the launch of its XPressMAX Cell-Free Protein Synthesis Kit on May 19, 2026. This innovative kit utilizes advanced cell-free protein synthesis technology to enable rapid and efficient in vitro production of target proteins and antibodies, eliminating the constraints of traditional cell-based expression systems. The kit is designed to integrate seamlessly with AI-powered screening platforms, accelerating the identification and optimization of antibody candidates, thereby reducing development timelines and costs. Dr. Rob Burgess and Dr. Zhang Jie of Sino Biological highlighted the kit's ability to achieve ultra-fast synthesis in 3 hours with a high success rate, supporting complex disulfide bonding. Sino Biological aims to help researchers compress antibody discovery timelines without compromising quality, serving researchers in over 90 countries.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard